The mRNA expression of METTL14 showed an increasing trend in IDH-wildtype GBM in the Microarray cohort, but there was no significant difference among different glioma subtypes in the RNA-seq cohort (Additional file 1: Fig. S1B). This evidence concerns the gene METTL14 and central nervous system cancer.